DGIdb - CTNNB1 Gene Record

CTNNB1 1499 Druggable GenomeClinically ActionableDrug Resistance

Alternate Names:

1499
CATENIN BETA 1
CTNNB1
CTNNB
EVR7
MRD19
armadillo
116806
2514
ENSG00000168036
OTTHUMG00000131393
PA27013
P35222
1290
Beta-catenin
T82795
NEDSDV
PRO2286
OK/SW-cl.35
Catenin beta-1

Gene Info:

Target Class	Miscellaneous
Target Subclass	StructuralAndAdhesion
Target Subclass	beta-Catenin
Gene Biotype	PROTEIN_CODING

(12 More Sources)

Gene Categories: Category Details

TRANSCRIPTION FACTOR COMPLEX
DRUG RESISTANCE
TRANSCRIPTION FACTOR BINDING
DRUGGABLE GENOME
CLINICALLY ACTIONABLE
TRANSCRIPTION FACTOR

Publications:

Arqués et al., 2016, Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer., Clin. Cancer Res.
Butrym A et al., 2015, Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment., Leuk Res
Henen MA et al., 2012, Toward rational fragment-based lead design without 3D structures., J Med Chem
Lee MA et al., 2013, Anti-proliferative activity of hydnocarpin, a natural lignan, is associated with the suppression of Wnt/β-catenin signaling pathway in colon cancer cells., Bioorg Med Chem Lett
Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
Kasper et al., 2016, Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01)., Ann. Surg. Oncol.
Gurney et al., 2012, Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors., Proc. Natl. Acad. Sci. U.S.A.
Myers et al., 2016, Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study., Gynecol. Oncol.
Peng et al., 2015, Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers., Cancer Cell

CHEMBL2172378 CTNNB1

Interaction Score: 6.71

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22889313

Sources:
DTC
FLUORESCEIN SODIUM CTNNB1

Interaction Score: 6.71

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22889313

Sources:
DTC
EOSIN_Y CTNNB1

Interaction Score: 6.71

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22889313

Sources:
DTC
CHEMBL91638 CTNNB1

Interaction Score: 3.36

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24018191

Sources:
DTC
TRICIRIBINE CTNNB1

Interaction Score: 1.34

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy NVP-TNKS656 + Triciribine

Indication/Tumor Type colon cancer

Response Type predicted – sensitive

PMIDs:
26224873

Sources:
JAX-CKB
VANTICTUMAB CTNNB1

Interaction Score: 0.96

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colon cancer

Response Type predicted – sensitive

Approval Status Preclinical - Pdx

PMIDs:
22753465

Sources:
JAX-CKB
LENALIDOMIDE CTNNB1

Interaction Score: 0.48

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26521987

Sources:
PharmGKB
TEMSIROLIMUS CTNNB1

Interaction Score: 0.45

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type endometrial cancer

Response Type predicted – sensitive

Approval Status Phase II

PMIDs:
27016228

Sources:
JAX-CKB
CHEMBL410484 CTNNB1

Interaction Score: 0.42

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL533293 CTNNB1

Interaction Score: 0.31

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DITHIAZANINE IODIDE CTNNB1

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LETROZOLE CTNNB1

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

Alteration CTNNB1:H36Y,S37C,S37Y,D32V

Drug family MTOR inhibitor;Hormonal therapy

combination therapy Everolimus;Letrozole

PMIDs:
None found

Sources:
CGI
THALIDOMIDE CTNNB1

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26521987

Sources:
PharmGKB
TRAMETINIB CTNNB1

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type liver cancer

Response Type resistant

Approval Status Preclinical

PMIDs:
26343583

Sources:
JAX-CKB
CELECOXIB CTNNB1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22336956

Sources:
PharmGKB
IMATINIB CTNNB1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Clinical Study

Response Type sensitive

PMIDs:
26861905

Sources:
JAX-CKB
CYCLOPHOSPHAMIDE CTNNB1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26521987

Sources:
PharmGKB
EVEROLIMUS CTNNB1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Everolimus;Letrozole

Drug family MTOR inhibitor;Hormonal therapy

Alteration CTNNB1:H36Y,S37C,S37Y,D32V

PMIDs:
None found

Sources:
CGI
DEXAMETHASONE CTNNB1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26521987

Sources:
PharmGKB

Ensembl: ENSG00000168036
- Version: 101_38
Alternate Names:

CTNNB1 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:
TdgClinicalTrial: P35222
- Version: January-2014
Alternate Names:

CTNNB1 Gene Symbol

Gene Info:

Target Class Miscellaneous

Target Subclass StructuralAndAdhesion

Target Subclass beta-Catenin

Publications:

JAX-CKB: CTNNB1

Version: 27-September-2017

Alternate Names:

1499 CKB Entrez Id

CTNNB1 CKB Gene Synonym

armadillo CKB Gene Synonym

Gene Info:

Publications:

Gurney et al., 2012, Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors., Proc. Natl. Acad. Sci. U.S.A.

Delgado et al., 2014, Identification and characterization of a novel small-molecule inhibitor of β-catenin signaling., Am. J. Pathol.

Tian et al., 2012, Structure-based discovery of a novel inhibitor targeting the β-catenin/Tcf4 interaction., Biochemistry

PharmGKB: CTNNB1

Version: 18-August-2020

Alternate Names:

PA27013 PharmGKB ID

Gene Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Butrym A et al., 2015, Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment., Leuk Res

CIViC: CTNNB1
- Version: 14-September-2020
Alternate Names:

1499 Entrez Gene ID

1290 CIViC Gene ID

Gene Info:

Gene Categories:

DRUG RESISTANCE

Publications:

Spranger et al., 2015, Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity., Nature
TTD: Beta-catenin
- Version: 2020.06.01
Alternate Names:

CTNNB1 TTD Gene Abbreviation

T82795 TTD Target ID

Gene Info:

Publications:

Burnett JC et al., 2011, Current progress of siRNA/shRNA therapeutics in clinical trials., Biotechnol J

DTC: CTNNB1

Version: 02-September-2020

Alternate Names:

Gene Info:

Publications:

Henen MA et al., 2012, Toward rational fragment-based lead design without 3D structures., J Med Chem

Lee MA et al., 2013, Anti-proliferative activity of hydnocarpin, a natural lignan, is associated with the suppression of Wnt/β-catenin signaling pathway in colon cancer cells., Bioorg Med Chem Lett

HingoraniCasas: ENSG00000168036
- Version: 31-May-2017
Alternate Names:

ENSG00000168036 Gene Symbol

CTNNB1 Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
Tempus: CTNNB1
- Version: 11-November-2018
Alternate Names:

CTNNB1 Gene Symbol

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
GO: CTNNB1
- Version: 01-May-2021
Alternate Names:

CTNNB GO Gene Synonym

OK/SW-cl.35 GO Gene Synonym

PRO2286 GO Gene Synonym

Gene Info:

Gene Categories:

TRANSCRIPTION FACTOR COMPLEX, DRUG RESISTANCE, TRANSCRIPTION FACTOR BINDING

Publications:
Pharos: CTNNB1
- Version: 01-May-2021
Alternate Names:

Catenin beta-1 Gene Name

P35222 UniProt ID

Gene Info:

Gene Categories:

TRANSCRIPTION FACTOR

Publications:
MskImpact: CTNNB1
- Version: May-2015
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
CGI: CTNNB1
- Version: 27-September-2017
Alternate Names:

Gene Info:

Publications:
FoundationOneGenes: CTNNB1
- Version: 03-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
CarisMolecularIntelligence: CTNNB1
- Version: 04-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
Oncomine: CTNNB1
- Version: v3
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:

combination therapy	NVP-TNKS656 + Triciribine
Indication/Tumor Type	colon cancer
Response Type	predicted – sensitive

Indication/Tumor Type	endometrial cancer
Response Type	predicted – sensitive
Approval Status	Phase II

Alteration	CTNNB1:H36Y,S37C,S37Y,D32V
Drug family	MTOR inhibitor;Hormonal therapy
combination therapy	Everolimus;Letrozole

Indication/Tumor Type	liver cancer
Response Type	resistant
Approval Status	Preclinical

Evidence Type	Actionable
Approval Status	Clinical Study
Response Type	sensitive

1499	CKB Entrez Id
CTNNB1	CKB Gene Synonym
armadillo	CKB Gene Synonym

CTNNB	GO Gene Synonym
OK/SW-cl.35	GO Gene Synonym
PRO2286	GO Gene Synonym

CTNNB1 Gene Record

CTNNB1 1499 Druggable GenomeClinically ActionableDrug Resistance

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22889313

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22889313

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22889313

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24018191

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info: combination therapy NVP-TNKS656 + Triciribine Indication/Tumor Type colon cancer Response Type predicted – sensitive

PMIDs: 26224873

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type colon cancer Response Type predicted – sensitive Approval Status Preclinical - Pdx

PMIDs: 22753465

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26521987

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type endometrial cancer Response Type predicted – sensitive Approval Status Phase II

PMIDs: 27016228

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info: Alteration CTNNB1:H36Y,S37C,S37Y,D32V Drug family MTOR inhibitor;Hormonal therapy combination therapy Everolimus;Letrozole

PMIDs: None found

Sources: CGI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26521987

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type liver cancer Response Type resistant Approval Status Preclinical

PMIDs: 26343583

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22336956

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Approval Status Clinical Study Response Type sensitive

PMIDs: 26861905

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26521987

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Everolimus;Letrozole Drug family MTOR inhibitor;Hormonal therapy Alteration CTNNB1:H36Y,S37C,S37Y,D32V

PMIDs: None found

Sources: CGI

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality:

n/a

PMIDs:
22889313

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22889313

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22889313

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
24018191

Sources:
DTC

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy NVP-TNKS656 + Triciribine

Indication/Tumor Type colon cancer

Response Type predicted – sensitive

PMIDs:
26224873

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colon cancer

Response Type predicted – sensitive

Approval Status Preclinical - Pdx

PMIDs:
22753465

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
26521987

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type endometrial cancer

Response Type predicted – sensitive

Approval Status Phase II

PMIDs:
27016228

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

Interaction Info:

Alteration CTNNB1:H36Y,S37C,S37Y,D32V

Drug family MTOR inhibitor;Hormonal therapy

combination therapy Everolimus;Letrozole

PMIDs:
None found

Sources:
CGI

Interaction Types & Directionality:

n/a

PMIDs:
26521987

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type liver cancer

Response Type resistant

Approval Status Preclinical

PMIDs:
26343583

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
22336956

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Clinical Study

Response Type sensitive

PMIDs:
26861905

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
26521987

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Everolimus;Letrozole

Drug family MTOR inhibitor;Hormonal therapy

Alteration CTNNB1:H36Y,S37C,S37Y,D32V

PMIDs:
None found

Sources:
CGI

Interaction Types & Directionality:

n/a

PMIDs:
26521987

Sources:
PharmGKB

Alternate Names:

CTNNB1 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Alternate Names:

CTNNB1 Gene Symbol

Gene Info:

Target Class Miscellaneous

Target Subclass StructuralAndAdhesion

Target Subclass beta-Catenin

Alternate Names:

1499 CKB Entrez Id

CTNNB1 CKB Gene Synonym

armadillo CKB Gene Synonym

Alternate Names:

PA27013 PharmGKB ID

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Butrym A et al., 2015, Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment., Leuk Res

Alternate Names:

1499 Entrez Gene ID

1290 CIViC Gene ID

Gene Categories:

DRUG RESISTANCE

Publications:

Spranger et al., 2015, Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity., Nature

Alternate Names:

CTNNB1 TTD Gene Abbreviation

T82795 TTD Target ID

Publications:

Burnett JC et al., 2011, Current progress of siRNA/shRNA therapeutics in clinical trials., Biotechnol J

Alternate Names:

ENSG00000168036 Gene Symbol

CTNNB1 Ensembl Id

Gene Categories:

DRUGGABLE GENOME

Alternate Names:

CTNNB1 Gene Symbol

Gene Categories:

CLINICALLY ACTIONABLE